China Innovation Investment (HKG:1217) said the proposed removal of certain directors the company appointed at Elife (HKG:0223) would constitute a breach of contract as per the subscription agreement entered by both parties, a Tuesday Hong Kong bourse filing said.
China Innovation Investment said the removal of certain directors would undermine its original intentions in investing in the company and contradict the mutual understanding between the two parties under the subscription agreement.
Certain minority shareholders of Ellife had proposed the removal of these directors and had asked for an extraordinary general meeting to be convened for its approval.
China Innovation Investment's shares closed over 8% higher on Tuesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。